RxDoctor Payments Data

Elam Safi, MD

Internal Medicine · Ware, MANPI 1780646141

Payments from drug & device makers

$1,454in general payments, 2019–2025

Across 95 payments — averaging $15.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$324
  • GSK$292
  • Boehringer Ingelheim$116
  • AbbVie$99
  • AstraZeneca$89
  • Novartis$79
  • plus $456 from 11 others

What the payments were for

  • Food & beverage$1,44599%
  • Education$91%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,454 in reported general payments places this provider in the 85th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$219,600
Medicare patients
236
Services billed
1,791

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban115$98,234
JardianceEmpagliflozin75$67,323
Trelegy ElliptaFluticasone/Umeclidin/Vilanter88$61,095
MounjaroTirzepatide45$46,793
FarxigaDapagliflozin Propanediol28$26,121
JanuviaSitagliptin Phosphate18$23,459
XareltoRivaroxaban23$23,129
TrulicityDulaglutide21$19,973
Combivent RespimatIpratropium/Albuterol Sulfate15$16,175
Spiriva RespimatTiotropium Bromide23$14,947
Tresiba Flextouch U-200Insulin Degludec16$13,708
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr24$10,978
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$9,374
Atorvastatin Calcium477$6,808
MyrbetriqMirabegron13$5,701

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Combivent Respimat, Spiriva Respimat$116$98,444113 claims
PfizerEliquis$324$98,234115 claims
GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$292$80,823135 claims
Lilly USA, LLCMounjaro, Trulicity$51$66,76666 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$89$40,14353 claims
Johnson & JohnsonXarelto$71$23,12923 claims
Astellas Pharma US IncMyrbetriq$66$5,70113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Ware

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →